申请人:SENTINEL ONCOLOGY LIMITED
公开号:US11208405B2
公开(公告)日:2021-12-28
The invention provides compounds of the formula (3):
or a pharmaceutically acceptable salt or tautomer thereof, wherein:
Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O;
ring X is a benzene or pyridine ring;
ring Y is a benzene, pyridine, thiophene or furan ring;
Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring;
m is 0, 1 or 2;
n is 0, 1 or 2;
R1 is selected from various substituents:
R2 is selected from hydrogen and a C1-4 hydrocarbon group;
R3 is selected from hydrogen and a C1-4 hydrocarbon group;
R4 is selected from various substituents;
R5 is selected from various substituents;
Ar2 is an optionally substituted phenyl, pyridyl or pyridone group;
R6 is a group Q1-Ra—Rb;
Q1 is absent or is a C1-3 saturated hydrocarbon linker;
Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc;
Rb is selected from hydrogen and various substituents;
and R7 is selected from R4.
The compounds are useful in the treatment of cancers.
本发明提供了式 (3) 的化合物:
或其药学上可接受的盐或同系物,其中
Z 是一个 5 元杂芳基环,含有一个或两个氮环成员,可选地还含有一个选自 N 和 O 的杂原子环成员;
环 X 是苯环或吡啶环;
环 Y 是苯、吡啶、噻吩或呋喃环;
Ar1 是任选取代的苯、吡啶、噻吩或呋喃环;
m 为 0、1 或 2;
n 为 0、1 或 2;
R1 选自各种取代基:
R2 选自氢和 C1-4 烃基;
R3 选自氢和 C1-4 烃基;
R4 选自各种取代基;
R5 选自各种取代基;
Ar2 是任选取代的苯基、吡啶基或吡啶酮基团;
R6 是 Q1-Ra-Rb 基团;
Q1 不存在或为 C1-3 饱和烃连接体;
Ra 选自 O、C(O)、C(O)O、CONRc、N(Rc)CO、N(Rc)CONRc、NRc 和 SO2NRc;
Rb 选自氢和各种取代基;
R7 选自 R4。
这些化合物可用于治疗癌症。